Published in final edited form as:

Ann Rheum Dis. 2019 July ; 78(7): 1004–1006. doi:10.1136/annrheumdis-2018-214559.

Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicenter cohort study

S Sciascia^{1,2}, J Yazdany³, M Dall'Era³, R Fenoglio², M Radin¹, I Aggarwal³, MJ Cuadrado^{4,5}, K Schreiber^{5,6,7}, A Barreca⁸, M Papotti⁸, and D Roccatello^{1,2}

¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy

²SCU Nephrology and Dialysis(ERKnet member), S. Giovanni Bosco Hospital, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy

³Division of Rheumatology, Russell/Engleman Research Center, University of California, San Francisco, San Francisco, California

⁴Lupus Unit, Department of Rheumatology, Guy's and St Thomas' Hospital, London, United Kingdom

⁵Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom.

⁶King Christian X's Rheumatology Hospital, Graasten, Denmark.

⁷Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen, Denmark.

⁸Division of Pathology, Department of Medical Sciences, University of Turin, Turin, Italy.

The management of lupus nephritis (LN) and concomitant thrombotic microangiopathy (TMA), with or without antiphospholipid antibodies (aPL), remains controversial and few studies are available to inform clinical management [1–4]

The purpose of this multicenter retrospective study was to analyze the impact of anticoagulation [vitamin-K-antagonists (VKA) and/or heparins] in addition to conventional immunosuppression on kidney outcomes (assessed at 12 months, according to KDIGO guidelines[5]) in patients with biopsy-proven LN and concomitant TMA.

Corresponding Author: Savino Sciascia, MD PhD, Center of Research of Immunopathology and Rare Diseases-CMID, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, and Nephrology and Dialysis Division (ERKnet member), Department of Clinical and Biological Sciences of the University of Turin, and San Giovanni Bosco Hospital, Turin, Italy, savino.sciascia@unito.it, Tel 00390112402051, Fax 00390112402052.

The authors declare no conflict of interest and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

Data source, population, and statistical analysis are detailed in the supplementary material. Anticoagulation was considered if given for at least 3 consecutive months after TMA diagnosis.

We retrospectively identified 97 patients with biopsy-proven LN and TMA (2007–2017). See online supplementary Table S1 for clinical and demographic characteristics. Laboratory parameters were collected at the time of the biopsy. The mean age of patients was 38.9 ± 15.2 years (13–69) and 85 female (87.6%). Most had proliferative LN (Class IV in 84.5%). Forty-two (43%) patients presented with acute and 55 (57%) with features of chronic TMA. All patients had received treatment with standard immunosuppressants (55% mycophenolate, 39% cyclophosphamide, 6% other regimen) and steroids. At 12 months, complete response (CR) was observed in 37 patients (38.1%), partial response (PR) in 22 (22.6%) and no response in 38 (39.1%). Sixty-one patients (62.9%) were aPL positive and 37 (38.1%) of these patients received anticoagulation with a VKA and/or heparins. Mean duration of anticoagulation therapy after TMA and LN diagnosis was 7.7 months (3–12).

We observed a higher rate of clinical response (CR/PR, together or computed separately) in patients who received anticoagulation [CR in 22 (59.46%), PR in 7 (18.91%); NR in 8 (21.62%)] when compared to those without [CR in 15 (25.0%), PR in 15 (25.0%); NR in 30 (50%)], $p < 0.01$ (Table 1).

When limiting the analysis on the 61 patients with aPL, we observed a higher rate of complete response in those receiving anticoagulation [patients receiving anticoagulant therapy: CR in 22 (59.46%), PR in 7 (18.91%); NR in 8 (21.62%) Vs. patients non receiving VKA/heparins: CR in 8 (30.77%), PR in 7 (26.92%); NR in 8 (34.62%), $p = 0.046$] (Figure 1).

After multivariate analysis, aPL positivity (any) ($\beta = 1.23$, OR, 2.4; 95% confidence interval-CI-, 1.2–7.3; $p = 0.03$), anti-dsDNA positivity ($\beta = 1.98$, OR, 12.8; 95% CI 3.0–71.3; $p = 0.002$), and chronic features of TMA ($\beta = 1.31$, OR 3.0; 95% CI 1.2–17.5; $p = 0.04$) were all associated with no kidney response.

When limiting the analysis to aPL positive patients, after adjusting for type of immunosuppressant therapy and LN class, variables that were significantly associated with CR+PR were features of acute TMA rather than chronic ($\beta = 1.95$, OR, 8.62; 95% CI 1.4–97.1; $p = 0.03$) and the use of VKA/heparins ($\beta = 1.21$, OR, 2.1; 95% CI, 1.02–16.2; $P = 0.046$).

In summary, in our study the use of anticoagulation was associated with any response to treatment at 1 year, in line with the fact that about 60% of the patients with CR received VKA or heparins. Similarly, when limiting the analysis to patients with aPL, we observed a rate of any response (either CR+PR) as high as 66% in patients receiving anti-coagulant treatment when compared to those receiving immunosuppression alone (34%).

Despite its limitations (the relatively short duration of follow-up to gauge the relapse rate; lack of standardized protocol for LN treatment; the use of anticoagulation agents was not randomized but based on the treating physicians' judgment), this study represents the largest

available multicentre cohort of real-life SLE patients with biopsy proven LN and concomitant TMA.

To conclude, in patients with concomitant LN and TMA, the use of anticoagulation appeared protective and warrants further investigation as a therapeutic tool; the presence of aPL, anti-dsDNA antibodies and chronic features of TMA were associated with poorer kidney outcomes.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

1. Mejía-Vilet JM, Córdova-Sánchez BM, Uribe-Uribe NO, et al. Prognostic significance of renal vascular pathology in lupus nephritis. *Lupus* 2017;26:1042–50. doi:10.1177/0961203317692419 [PubMed: 28178879]
2. Pattanashetti N, Anakutti H, Ramachandran R, et al. Effect of Thrombotic Microangiopathy on Clinical Outcomes in Indian Patients With Lupus Nephritis. *Kidney Int reports* 2017;2:844–9. doi: 10.1016/j.ekir.2017.04.008
3. Sciascia S, Cuadrado MJ, Khamashta M, et al. Renal involvement in antiphospholipid syndrome. *Nat Rev Nephrol* 2014;10:279–89. doi:10.1038/nrneph.2014.38 [PubMed: 24642799]
4. Moroni G, Ventura D, Riva P, et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. *Am J Kidney Dis* 2004;43:28–36. <http://www.ncbi.nlm.nih.gov/pubmed/14712424> (accessed 2 Apr 2018). [PubMed: 14712424]
5. KDIGO Clinical Practice Guideline for Glomerulonephritis KDIGO Clinical Practice Guideline for Glomerulonephritis KDIGO Clinical Practice Guideline for Glomerulonephritis. Published Online First: 2012. http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-GN-Guideline.pdf (accessed 4 Jun 2018).

Figure 1.

Comparison of kidney outcomes between patients receiving anticoagulation and those without (Panel A, all 97 patients; Panel B, limiting to patients positive for antiphospholipid antibodies)

Table 1.

Univariate analysis of patient characteristics by kidney outcome

Characteristics	Total	%	Any response	%	CR	%	%CR	PR	%	%PR	NR	%	%NR	p	*p
Female	85	87.6	52	53.6	30	30.9	81.1	22	22.68	100	33	34.02	86.84	0.2924	0.85
Clinical features															
APS *	13	13.4	10	10.3	5	5.2	13.5	5	5.2	22.7	3	3.1	7.9	0.2629	0.22
aPL antibody positivity	61	62.9	26	26.8	15	15.5	40.5	11	11.3	50.0	35	36.1	92.1	<0.001	<0.001
LAC	37	38.1	17	17.5	7	7.2	18.9	10	10.3	45.5	20	20.6	52.6	0.0079	0.018
aCL	35	36.1	20	20.6	8	8.2	21.6	12	12.4	54.5	15	15.5	39.5	0.0334	0.57
anti-Beta2GPI	22	22.7	12	12.4	7	7.2	18.9	5	5.2	22.7	10	10.3	26.3	0.7464	0.49
Triple Positivity	15	15.5	8	8.2	5	5.2	13.5	3	3.1	13.6	7	7.2	18.4	0.811	0.51
Anti-dsDNA	43	44.3	22	22.7	13	13.4	35.1	9	9.3	40.9	24	24.7	63.2	0.041	0.0214
Low C3 levels	77	79.3	36	37.1	25	25.8	67.6	11	11.3	50.0	38	39.2	100.0	0.001	<0.001
Low C4 levels	27	27.8	15	15.5	8	8.2	21.6	7	7.2	31.8	12	12.4	31.6	0.5627	0.64
Arterial hypertension	63	64.9	36	37.1	23	23.7	62.2	13	13.4	59.1	28	28.9	73.7	0.4252	0.27
Hyperlipemia	45	46.3	27	27.8	17	17.5	45.9	10	10.3	45.5	18	18.6	47.4	0.98	1
aGAPSS 12	24	24.7	10	10.3	6	6.2	16.2	4	4.1	18.2	14	14.4	36.8	0.0846	0.0267
LN class IV	82	84.5	50	51.5	32	33.0	86.5	18	18.6	81.8	32	33.0	84.2	0.8891	1
Therapy															
Mycophenolate mofetil	53	54.6	32	33.0	21	21.6	56.8	11	11.3	50.0	21	21.6	55.3	0.8764	1
Cyclophosphamide	38	39.2	22	22.7	14	14.4	37.8	8	8.2	36.4	16	16.5	42.1	0.888	0.67
EUROLUPUS regimen	28	28.9	16	16.5	11	11.3	29.7	5	5.2	22.7	12	12.4	31.6	0.7583	0.65
Other immunosuppressants	6	6.2	4	4.1	2	2.1	5.4	2	2.1	9.1	2	2.1	5.3	0.8128	1
Anticoagulation	37	38.1	29	29.9	22	22.7	59.5	7	7.2	31.8	8	8.2	21.1	0.0022	0.0059

* computing together any response, CR+PR, CR, complete response; PR, partial response; NR, no response; aGAPSS, adjusted global antiphospholipid score.